Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lebrikizumab in Moderate-to-Severe Atopic Dermatitis (Randomized, Double-Blind, Placebo-Controlled, Phase 3)
2019-002932-10Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Lebrikizumab with Placebo (2 arms). Primary endpoint: Investigator Global Assessment (IGA) response at Week 16. Started Dec 2019; status: completed.
02
Drugs
lebrikizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2019-002932-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002932-10.